BIOHIT OYJ STOCK EXCHANGE RELEASE 14 MAY 2009 AT 5:00 PM PETER TCHERNYCH, NEW DIRECTOR FOR BIOHIT'S DIAGNOSTICS BUSINESS Peter Tchernych, MSc. econ., LL.M., (52), has been appointed Director of Biohit Oyj's diagnostic business segment as of 1st June 2009. Prior to joining Biohit, Mr Tchernych has been working for GE Healthcare, most recently as Managing Director, Market Development in GE Healthcare International. He has almost 20 years experience from different sales, marketing and business development leadership positions within the healthcare technology industry. Mr Tchernych was also member of the Board of Biohit Oyj during 2003-2007. Further information: Osmo Suovaniemi, M.D., Ph.D., Professor President & CEO Tel: +358-9-773 861 Email: osmo.suovaniemi@biohit.com Jussi Heiniö, VP Administration & Legal Affairs Tel: +358-9-773 861 Email: jussi.heinio@biohit.com Distribution: NASDAQ OMX Helsinki Oy Central storage facility (www.oam.fi) Press www.biohit.com About Biohit Oyj Biohit Oyj develops, manufactures and markets liquid handling products and diagnostic test systems for use in research, health care and industrial laboratories. Liquid handling products include electronic and mechanical pipettes and dispensers, and disposable tips, as well as pipette maintenance and calibration services. Diagnostics business comprises products and analysis systems for diagnosing, screening and prevention of gastrointestinal diseases, e.g. the blood-sample based GastroPanel and GastroView, for diagnosing diseases of the stomach and associated risks, as well as quick tests for the diagnosis of lactose intolerance, H. pylori infection and fecal occult blood. Biohit Oyj is headquartered in Finland. Biohit has subsidiaries in France, Germany, the UK, Russia, China, Japan and the USA. Additionally, Biohit's products are sold by approximately 450 distributors in 70 countries. Biohit's share (BIOBV) is quoted on NASDAQ OMX Helsinki. Read more at www.biohit.com